• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Better Q2 EBITDA At Gerresheimer (XTRA:GXI) Has Changed Its Investment Story

    Simply Wall St·10/02/2026 09:27:45
    Listen to the news
    • Gerresheimer reported first quarter 2026 sales of €474.94 million and a net loss of €98.32 million, and later highlighted a sharp sequential improvement in second quarter adjusted EBITDA along with plans to sell its Centor unit and Primary Packaging Plastics business.
    • The mix of weaker first quarter profitability and later commentary about better adjusted EBITDA and portfolio reshaping gives investors a clearer read on current execution pressures, cost discipline and how asset disposals might reshape Gerresheimer’s earning power over time.
    • We will explore how Gerresheimer’s investment narrative is affected by the reported adjusted EBITDA improvement as management outlines planned asset disposals.

    Spot emerging portfolio reshapes such as Gerresheimer’s, then scan a hand-picked universe of potential counterparts with the 616 high quality undiscovered gems that share strong fundamentals but receive relatively little attention.

    Gerresheimer Investment Narrative Recap

    To stay on board with Gerresheimer, you need to believe the packaging and drug delivery platform can convert its large revenue base into consistent profitability despite recent losses. The sharp sequential improvement in adjusted EBITDA that management highlighted signals early traction in the GTO transformation and cost work, which supports that thesis in the near term.

    The key short term catalyst is whether that EBITDA momentum shows up cleanly in reported earnings, while the Bormioli integration and new capacity ramps hold together operationally. The biggest risk remains financial pressure from weak first quarter profitability and higher leverage, especially if cash flow seasonality and moulded glass demand challenges persist.

    The most relevant recent update is management’s plan to sell the Centor unit and the Primary Packaging Plastics business while reshaping the balance sheet. These moves sit alongside the GTO program and Bormioli Pharma integration, so they matter for how focused Gerresheimer becomes on higher value pharma and biotech containment and delivery solutions.

    For you as an investor, the planned disposals intersect directly with the main catalysts and risks. Execution on these sales, the timing of closing, and any impact on debt paydown or interest cover will influence how comfortable the market feels with Gerresheimer’s leverage and its ability to fund Skopje, Peachtree City, and other growth projects without stretching liquidity.

    Gerresheimer's current revenue forecasts point to about €2.5 billion in sales and €62.9 million in earnings by 2029. This implies analysts are assuming yearly top line growth of 2.2% and an earnings swing of roughly €383 million from earnings today of a €320.3 million loss.

    Uncover why Gerresheimer's fair value is effectively aligned with its current price.

    XTRA:GXI 1-Year Stock Price Chart
    XTRA:GXI 1-Year Stock Price Chart

    Exploring Other Perspectives

    For Gerresheimer, the sharpest alternate take focuses on rising production and regulatory costs squeezing future cash generation. The most cautious analysts were assuming revenue would drift to about €2.0b by 2029 and still plugged in roughly €222.3 million of earnings. That is a far gloomier setup than consensus, and this new Q2 information may push those views to adjust.

    Explore 4 other Gerresheimer fair value estimates, including one that suggests as much as 28% downside from the current price.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment outcomes rarely result from following the herd, so trust your own analysis.

    Looking for more Gerresheimer style investment ideas?

    If Gerresheimer has sharpened your focus on quality, balance sheet strength and forward earnings potential, it can help to widen the lens and compare it with other stocks that share similar financial traits.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.